Full-Time

Senior Manager

Commercial Effectiveness

Posted on 10/31/2025

Invivyd

Invivyd

51-200 employees

Develops monoclonal antibodies for viral protection

No salary listed

New Haven, CT, USA

In Person

Category
Growth & Marketing (6)
, , , , ,
Required Skills
Data Analysis
Requirements
  • Bachelor's Degree required
  • 5 years of experience in a pharmaceutical/biotech company
  • Exceptional understanding of Commercial Effectiveness activities
  • Strong interpersonal skills with experience in conflict management and negotiation
  • Solid analytical and critical thinking skills. Is forward-thinking and can take a holistic view of the business in order to ensure efficiencies and alignment with Marketing and other cross functional teams
  • In depth expertise in Pharmaceutical Promotional/Marketing Services and knowledge of related disciplines - Pharmaceutical Marketing, Medical, Managed Markets, Marketing Agencies, Sourcing
  • Veeva Vault and PromoMats experience required
  • Strong communication skills, both verbal and written
  • Works with a sense of urgency, efficiency, and attention to detail
  • Demonstrated program ownership and consistent delivery on commitments
  • Solid understanding regarding the details of planning and executing NSM, POAs, etc.
  • Ability to work cross-functionally and with all levels of the organization, including Senior Leadership
  • Solid management skills with ability to provide clear guidance, direction and feedback
  • Experience in print production within a pharmaceutical company or advertising agency
  • Strong computer aptitude and ability to learn systems quickly. Veeva Vault experience a plus
  • Thrives in fast-paced, minimally structured environment, able to deal with ambiguity and can act without having the complete picture
  • Ability to self-direct projects and work with little supervision
  • Experience managing vendor partners/consultants and leading project teams to achieve milestones and objectives
  • Ability to travel to New Haven, CT 2-3x a month
Responsibilities
  • Set vision and direction for the PRC process
  • Develop, build and manage the technical infrastructure to support all PRC processes, materials management/review and approved outputs
  • Own cross-functional forecasting and prioritization process for all incoming PRC submissions (with marketing and other groups submitting). Proactively escalate issues as needed
  • Manage and support other functions to plan and prioritize material development and review. Inform stakeholders of activity relative to printing and fulfillment by providing quarterly utilization metrics and analysis
  • Owns and ensures adherence to all PRC process requirements. Responsible for creation and communication of key PRC process updates. Manage project owners/agencies to ensure materials are submitted correctly and in a timely manner; identify any areas for improvement and provide actionable feedback
  • Owns all training for internal stakeholders and agency partners on process and system responsible for change management and adherence to updates. Proactively partners with PRC Lead(s) and Agency of Record to identify where additional training may be required
  • Owns launch and/or label update project management ensuring all contributors are aligned on a plan and held accountable to execute
  • Print and fulfillment
  • Responsible for the production and distribution of the promotional materials (print and fulfillment). Proactively manage all vendors and continually ensure that business rules are being met, and budgets are reported accurately monthly.
  • Evaluate print/fulfillment model and refine as needed to drive efficiency and compliance in print materials and inventory set-up.
  • Define metrics strategy to track, monitor and manage print inventory and cost savings (usage, destruction, and expiration.) Lead ongoing audits of material, providing key data inputs to drive decisions.
  • Field-based Educational Programs (peer-to-peer)
  • Maintain an educational program process in coordination with Marketing, Compliance and Sales leadership. Owns all operational aspects of program execution including budgeting, planning, execution and closure.
  • Develops and manages with Compliance a program audit process.
  • Select and manage vendor partners, technologies and Standard Operating Procedures (SOPs).
  • Develop comprehensive training for all aspects of the educational programs including contracted speakers, field execution and audit procedures.
  • Build performance dashboard for leadership team and conduct quarterly reviews.
  • Commercial Transparency Reporting
  • Liaise with Corporate Compliance to:
  • - Ensure all commercial activities, systems and processes are compliant (i.e. Educational programs, Commercial Travel & Entertainment and Meeting/Congresses).
  • - Appropriate SOPs and training are conducted on proper reporting procedures
  • - Build and manage an aggregate spend and transparency reporting structure for all of Commercial with cross-functional partnership from Medical, Compliance, Legal, Patient Services, Market Access, Corp Comms, and IT.
  • - Includes SOPs, training, auditing, system integrations, vendor selection, etc.

Invivyd develops antibody-based therapies to protect immunocompromised people from viral threats. It discovers and optimizes monoclonal antibodies using viral surveillance, predictive modeling, and antibody engineering, aiming to prevent infections such as COVID-19 in high-risk groups. Its lead candidate VYD222 targets prevention of symptomatic COVID-19 in transplant recipients and people with blood cancers. The company plans to commercialize these antibodies through development, approvals, and partnerships, while pursuing government funding to support research for vulnerable populations.

Company Size

51-200

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2020

Simplify Jobs

Simplify's Take

What believers are saying

  • DECLARATION Phase 3 trial fully enrolled with mid-2026 data readout for VYD2311 launch.
  • PEMGARDA revenue grew 31% sequentially in Q4 2025, validating antibody prophylaxis market demand.
  • Pipeline expansion into measles, RSV, and long COVID addresses multiple high-need viral indications.

What critics are saying

  • Low COVID community attack rates force 30% trial expansion, risking 6-9 month data delay.
  • Stock price below $1 triggers Nasdaq delisting risk, halting institutional investment and capital access.
  • Competing extended half-life COVID antibodies from AstraZeneca and Regeneron capture immunocompromised market share.

What makes Invivyd unique

  • Proprietary platform combines viral surveillance, predictive modeling, and antibody engineering for evolved immunity.
  • Targets immunocompromised populations underserved by traditional vaccines with monoclonal antibody prophylaxis.
  • FDA Fast Track designation for VYD2311 accelerates COVID-19 prevention development versus competitors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Professional Development Budget

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-5%

2 year growth

-1%
Yahoo Finance
Mar 5th, 2026
Invivyd eyes mid-2026 data for COVID antibody VYD2311 as PEMGARDA revenue jumps 31%

Invivyd reported Q4 2025 earnings, highlighting strategic progress in monoclonal antibody prophylaxis as an alternative to COVID-19 vaccine boosting. The company's Declaration study for VYD2311 reached target enrolment of approximately 1,770 subjects, with mid-year 2026 remaining the target for pivotal data. PEMGARDA revenue grew 31% sequentially, supporting infrastructure development ahead of a potential VYD2311 launch. Management expects to decide on expanding the trial by roughly 30% in April to ensure statistical power if community attack rates fluctuate. The company reported cash of $226.7 million, providing runway through the mid-2026 data readout. Invivyd is expanding into long COVID and post-vaccine syndrome, whilst developing RSV and measles programmes with a paediatric-first approach. Management cited COVID-19 community attack rates as the primary external risk factor.

Yahoo Finance
Mar 5th, 2026
Invivyd appoints Harvard epidemiologist Michael Mina as chief medical officer

Invivyd has appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer. Dr Mina is a former assistant professor of epidemiology, immunology and infectious disease at Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital. Dr Mina gained prominence during the COVID pandemic, advising governments on testing policies and leading the US government's Home Test-to-Treat Programme. His research includes discovering measles-induced "immune amnesia" and investigating antibody responses to vaccines and pathogens. He has published over 100 scientific papers with more than 10,000 citations. The appointment comes as Invivyd works to expand its pipeline of monoclonal antibodies for infectious disease prevention, including COVID, RSV and measles.

Yahoo Finance
Mar 5th, 2026
Invivyd reports $17.2M Q4 revenue for PEMGARDA, raises $200M to fund VYD2311 COVID trial

Invivyd reported fourth quarter 2025 net product revenue of $17.2 million for PEMGARDA (pemivibart), representing 25% year-over-year growth and 31% quarter-over-quarter growth. Full-year revenue more than doubled whilst operating expenses were reduced by nearly half. The company ended 2025 with $226.7 million in cash after raising over $200 million in financing transactions during the second half of the year. Invivyd has initiated the DECLARATION Phase 3 pivotal trial of VYD2311, a vaccine-alternative antibody to prevent COVID, with top-line data expected mid-2026. The FDA granted Fast Track designation for VYD2311 in December 2025. The trial has achieved full enrolment and an independent data monitoring committee has recommended allowing pregnant and breastfeeding women to participate. A potential trial re-sizing decision could occur in April.

TipRanks
Nov 17th, 2025
Invivyd Announces Common Stock Offering

Invivyd announced an underwritten public offering of its common stock, with all shares offered by the company. The proceeds will be used for commercial preparedness for VYD2311, R&D for pipeline programs like respiratory syncytial virus and measles, advancement of the SPEAR Study Group on monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, and general corporate purposes. Cantor is the sole book-running manager for the offering.

Stock Titan
Aug 22nd, 2025
Invivyd Closes $57.5M Public Offering

Invivyd has announced the successful closing of a public offering, raising $57.5 million. The underwriter also fully exercised their option to purchase additional shares.

INACTIVE